TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt by Szegezdi, E et al.
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and
involves modulation of death receptor components and Akt
E Szegezdi
1,2, S Cahill
1,2, M Meyer
1,2, M O’Dwyer
3 and A Samali*,1,2
1Department of Biochemistry, National University of Ireland,University Road, Galway, Ireland;
2The National Centre for Biomedical Engineering Science,
National University of Ireland, University Road, Galway, Ireland;
3Department of Haematology, University College Hospital Galway, Newcastle Road,
Galway, Ireland
The majority of leukaemic cells are resistant to apoptosis induced by tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL). Here, we show that sublethal concentrations of arsenic trioxide (ATO) specifically enhanced TRAIL-induced apoptosis in
leukaemic but not in other tumour cell lines. The combination of ATO and TRAIL synergistically enhanced cleavage of caspase-8,
which was blocked by the caspase inhibitor IETD.fmk as well as in cells deficient for caspase-8, suggesting a requirement for the death-
inducing signalling complex. Arsenic trioxide led to increased cell surface expression of DR5 (death receptor 5), inhibition of the
serine/threonine kinase Akt and downregulation of the short isoform of FLIP (FLICE-inhibitory protein, FLIPS). Inhibition of the
phosphatidylinositol 3 kinase (PI3K) was equally efficient in sensitising leukaemic cells to TRAIL with similar effects on DR5 and FLIPS
expression, suggesting that ATO may in part act through inhibition of the PI3K/Akt signalling pathway. These results indicate that the
enhancement in TRAIL-mediated apoptosis induced by ATO is due to alteration in the levels of multiple components and regulators
of the death receptor-mediated pathway. These findings offer a promising and novel strategy involving a combination of TRAIL and
ATO, or more specific Akt inhibitors in the treatment of various haematopoietic malignancies.
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The outcome of adult patients with acute leukaemia has changed
little over the past 20 years, especially in older patients (460
years) in whom intensive chemotherapy is frequently inappropri-
ate and survival poor. Development of less-toxic, targeted
approaches is clearly necessary. One such emerging anticancer
agent is the tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL). Tumour necrosis factor-related apoptosis-indu-
cing ligand is a member of the TNF death ligand family, which can
interact with four distinct membrane-bound receptors (DR4/
TRAIL-R1, DR5/TRAIL-R2, DcR1/TRAIL-R3 and DcR2/TRAIL-R4)
(Wiley et al, 1995; Ashkenazi and Dixit, 1999). DR4 and DR5
contain a conserved cytoplasmic region called the death domain
(DD) that is required for TRAIL-induced apoptosis. DcR1 does not
have a cytoplasmic domain, whereas DcR2 contains a truncated
DD motif (Ashkenazi and Dixit, 1999). Thus, DcR1 and DcR2 act as
decoy receptors, and ligation of only DR4 or DR5 initiates
apoptosis.
Binding of TRAIL to DR4 or DR5 leads to receptor trimerisation
and assembly of the death-inducing signalling complex (DISC).
Caspase-8 is recruited to the DISC where it becomes activated
(Ashkenazi and Dixit, 1999; MacFarlane, 2003). Subsequent events
can follow two apoptotic-signalling pathways. In the first scenario
(type I cells), caspase-8 directly activates effector caspases
(caspase-3, -6, -7), while in type II cells, caspase-8 engages the
mitochondrial pathway by activating Bid (Sartorius et al, 2001).
Tumour necrosis factor-related apoptosis-inducing ligand is an
attractive antineoplastic agent as it preferentially induces apoptosis
in transformed cells, with little effect on normal cells (Lawrence
et al, 2001; Almasan and Ashkenazi, 2003). Additionally, TRAIL
may overcome drug resistance due to dysfunction of the p53
pathway or overexpression of Bcl-2 family members (Walczak et al,
2000; Nagane et al, 2001). However, response to TRAIL is highly
variable with resistance seen in many cancer types, including
leukaemia (Ehrhardt et al, 2003). Potential mechanisms of
resistance include poor expression of DR4 and/or DR5 or increased
expression of decoy receptors and c-FLIP (FLICE-inhibitory
protein) (Sheridan et al, 1997; Jin et al, 2004; Ricci et al, 2004).
In type II cells due to the requirement for intrinsic pathway
amplification, TRAIL resistance also can be mediated at the level of
the mitochondria by Bcl-2 and Bcl-XL (Korsmeyer, 1992). Finally,
overexpression of inhibitor of apoptosis proteins (IAP) can prevent
TRAIL-induced apoptosis through inhibition of effector caspases
(caspase-3, -6 and -7) (Aggarwal et al, 2004). Notably, the
expression of these different antiapoptotic proteins may be
regulated by several different signal transduction pathways
including Akt, NF-kB and p53, which are frequently activated in
leukaemias (Shankar and Srivastava, 2004). Strategies to overcome
these mechanisms of resistance are the subject of intensive
investigation. A variety of anticancer modalities including cytotoxic
chemotherapy, radiation and novel therapies were shown to have
additive or synergistic effects with TRAIL (Sayers et al, 2003;
Ganten et al, 2004; Inoue et al, 2004; Rosato et al, 2004). However,
in most of these studies, no mechanistic insight was provided.
Based on a recent report demonstrating synergy between arsenic
trioxide (ATO) and TRAIL in myeloma cells, we were interested in
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sexploring the potential of ATO as a TRAIL-sensitising agent in
leukaemic cells (Liu et al, 2003). Arsenic trioxide has pleiotropic
mechanisms of action. Differential effects with respect to induction
of differentiation and apoptosis have been described, which appear
to be dose dependent (Chen et al, 1996). At low, clinically
achievable concentration, ATO has demonstrated marked activity
in acute promyelocytic leukaemia (APL) with little toxicity (Niu
et al, 1999; O’Dwyer et al, 2002). In other haematological
malignancies however, as a single agent, ATO has only a modest
activity, although it may have a greater role in combination with
other drugs (Evens et al, 2004).
We examined a selection of tumour cell lines, (including three
leukemic cell lines) looking for evidence of synergy between ATO
and TRAIL and specifically, to identify the cellular mechanisms
underlying this effect. In all three leukaemic cell lines tested, ATO
augmented TRAIL-induced cell death. This could be blocked by
inhibition or absence of caspase-8 suggesting a requirement for the
DISC complex. Arsenic trioxide increased cell surface expression
of DR5, inhibited phosphorylation of Akt and led to down-
regulation of the short isoform of FLIP (FLIPS). Inhibition of the
PI3K was equally efficient in sensitising leukaemic cells to TRAIL
with similar effects on DR5 and FLIPS expression, suggesting that
ATO may act through inhibition of the PI3K/Akt signalling
pathway. These results point out that the combination of TRAIL
and ATO, or more specific Akt inhibitors may be valuable in the
treatment of various haematopoietic malignancies.
MATERIALS AND METHODS
Cell culture and treatments
Jurkat, caspase-8-deficient Jurkat (Juo et al, 1998), ML-1, K562,
Raji and Colo205 cells were cultured in RPMI medium. PC3, HeLa,
cells were cultured in DMEM medium. Both media were
supplemented with 10% foetal bovine serum, 2mM glutamine,
50Uml
 1 penicillin and 5mgml
 1 streptomycin, RPMI medium
was also supplemented with 1mM Na-pyruvate. To induce
apoptosis, cells were treated with various concentrations of
recombinant TRAIL (soluble TRAIL (aa 114–281) was a kind gift
from Professor Wim J Quax, University of Groningen, Groningen,
the Netherlands) in the presence or absence of increasing
concentration of ATO (100–1000ngml
 1, 0.5–5mM) for the
indicated time periods. The PI3K inhibitor LY294002 (Calbiochem,
Schwalbach, Germany) and the caspase inhibitor IETD.fmk
(Enzyme Systems Products, Livermore, CA, USA) were added 1h
prior to treatment with TRAIL at a final concentration of 20mM. All
other reagents were from Sigma-Aldrich, St Louis, MO, USA,
unless indicated otherwise.
Western blot analysis
Cells were lysed in a buffer containing 20mM HEPES, pH 7.5,
350mM NaCl, 1mM MgCl2, 0.5mM EDTA, 0.5mM EGTA, 1% NP-
40, 0.5mM dithiothreitol (DTT), 100mM PMSF (phenylmethane-
sulphonyl fluoride), 2mgml
 1 pepstatin A, 25mM ALLN,
2.5mgml
 1 aprotinin and 10mM leupeptin. Proteins were separated
by electrophoresis on 10% SDS–polyacrylamide gels and then
transferred onto nitrocellulose membranes. After blocking in 5%
nonfat milk, 0.05% Tween-20 in PBS, blots were incubated with
1:1000 dilution of antibodies to caspase-8, P-Akt (Ser 473), Akt
(all from Cell Signaling Technology, Danvers, MA, USA), c-FLIP
(Stressgen, Victoria, BC, Canada) and 1:500 dilution of rabbit
polyclonal antibody against b-actin (Sigma, St Louis, MO, USA).
The appropriate horseradish peroxidase-conjugated goat second-
ary antibodies (Pierce, Rockford, IL, USA) were used at a 1:5000
for primary antibodies from Cell Signaling Technologies and at a
1:10000 dilution for all other antibodies. Protein bands were
detected with Super Signal Ultra Chemilumiescent Substrate
(Pierce) on X-ray film (Agfa, Mortsel, Belgium).
Haematoxylin–Eosin staining and microscopy
After treatments, cells were spun onto microscope slides, fixed in
methanol for 5min at room temperature and were stained by
immersion in Harris haematoxylin solution for 5min followed
by 1min immersion in Eosin Y. The slides were mounted using
DPX. Phase contrast images were taken from 15 randomly chosen
areas per sample using 400  overall magnification (Zeiss S100
Microscope). For data acquisition, the AQM acquisition manager
program was used.
Caspase activity assay
Cells were harvested by centrifuging at 450g for 5min. After two
washes in PBS, duplicate samples of 25ml were transferred to a
microtitre plate and snap-frozen over liquid nitrogen. To initiate
the reaction, 50mM of the caspase substrate Ac-Ile-Glu-Thr-Asp-a-
(4-methyl-coumaryl-7-amide) (IETD-AMC) (Peptide Institute Inc.,
Osaka, Japan) in assay buffer (100mM HEPES, 10% sucrose, 5mM
DTT, 0.0001% NP-40 and 0.1% 3-[(3-cholamidopropyl) dimethyl-
ammonio] propane-1-sulphonic acid (CHAPS), pH 7.25) was
added to the cell lysates. Liberated AMC was measured at 371C
kinetically every 60s, for 25 repeats on a Wallac Victor
2 plate
reader using excitation and emission wavelengths of 355 and
460nm, respectively. Enzyme activity was expressed as nanomole
AMC released per minute per mg of protein.
MTT assay
MTT dye (250mgml
 1) was added to control and treated cells and
incubated for 3h at 371C. The reaction was stopped and the blue
formazan precipitate formed was dissolved using 20% SDS in 50%
dimethylformamide. The colour intensity was measured at 550nm
on a Wallac Victor
2 plate reader. The control value corresponding
to untreated cells was taken as 100% and the viability of treated
samples was expressed as a percentage of the control.
Table 1 Semiquantitative representation of TRAIL and ATO sensitivity of tested cell lines
Cell line Origin TRAIL sensitivity Synergism with ATO
PC3 Prostate adenocarcinoma +++ +
HeLa Cervical adenocarcinoma + +
Colo205 Colon adenocarcinoma +++++ +
Raji Burkitt’s lymphoma + +
ML-1 Acute myeloid leukaemia +++ +++++
K562 Chronic myelogenous leukemia + +++++
Jurkat Acute T-cell leukaemia ++ +++++
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sApoptosis detection assay
Cells were treated with TRAIL and ATO for 6–12h and PS
(phosphatidyl serine) exposure was measured using annexin-V-
FITC (IQ Corporation, Groningen, The Netherlands) as described
earlier (Concannon et al, 2005). Briefly, cells were collected by
centrifugation at 350g, washed once in ice-cold calcium buffer
(10mM HEPES/NaOH, pH 7.4, 140mM NaCl, 2.5mM CaCl2) and
incubated with annexin V-FITC for 15min on ice. A wash step in
calcium buffer was carried out prior to acquisition on a
FacsCalibur flow cytometer (Becton Dickinson, Franklin Lakes,
NJ, USA).
Cell surface expression of TRAIL receptors
Cells were washed twice in PBS containing 1% BSA and then
incubated with monoclonal antibodies to DR4, DR5, DcR1 and
DcR2 (Alexis, Lausen, Switzerland) for 40min. After two wash
steps with PBS/BSA, anti-mouse IgG-FITC (Sigma) secondary
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Figure 1 Tumour necrosis factor-related apoptosis-inducing ligand and ATO has synergistic cytotoxic effect in leukaemic cells. Seven tumour cell lines
were treated with TRAIL in the presence of increasing concentration of ATO for 24h. Cell viability was measured by MTT assay. The graphs show the
average cell viability 7s.d. from three independent experiments expressed as percentage of untreated cells.
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santibody was added for 30min. All incubations were carried out at
room temperature. Negative controls contained only secondary
antibody. Cell surface expression was analysed by a FacsCalibur
flow cytometer.
RESULTS
Synergistic cytotoxic effect of TRAIL and ATO on
leukaemic cells
We examined whether treatment with sublethal doses of ATO can
sensitise tumour cells to TRAIL-induced apoptosis. A panel of
seven human cancer cell lines was tested, including three
adenocarcinomas, a B-cell lymphoma and three leukaemias.
Treatment with TRAIL alone revealed varying sensitivity between
the different cell types. The most TRAIL-sensitive of the seven cell
lines was the Colo205 colon adenocarcinoma cell line, where
10ngml
 1 TRAIL caused almost 100% cell death within 24h. The
myeloid leukaemia ML-1 and the prostate adenocarcinoma PC3
cells were also sensitive but required 200ngml
 1 TRAIL over 24h
for 90% cell death. In the remaining cell lines, TRAIL could not
induce more than 20% cell death over 24h even at the highest
concentration used (1.25mgml
 1) (Table 1).
To test the effect of ATO on TRAIL sensitivity of these tumour
cells, for each cell line the lowest TRAIL concentration that caused
10–20% cell death was determined. Using this TRAIL concentra-
tion, the cells were treated with increasing concentration of ATO
(100–1000ngml
 1, i.e. 0.5–5mM) for 24h and cell viability was
determined with MTT assay (Figure 1). In case of the TRAIL-
resistant cell lines, the highest TRAIL concentration (1.25mgml
 1)
was also tested, but no difference was observed (Figure 1). Of the
seven cell lines, none of the adenocarcinomas responded to ATO
treatment with increased TRAIL sensitivity (Table 1). However,
all three leukaemia cell lines (Jurkat, ML-1 and K562) showed
enhanced cell death in response to the combined treatment.
Phosphatidyl serine exposure measured by the extent of annexin V
binding confirmed the synergistic death-inducing effect of TRAIL
and ATO in the three leukaemic cell lines. In Jurkat cells, 12h
treatment with TRAIL or ATO induced 15% and 12% annexin V
positivity, respectively. However, the combined treatments led to
69% positivity in 12h. Similar results were obtained in ML-1 and
K562 cells (Figure 2A). Cell death induced by the combined
treatment displayed features of apoptosis, including blebbing,
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Figure 2 Combined treatment with TRAIL and ATO has synergistic apoptosis-inducing effect. Cells were treated with sublethal dose of TRAIL (Jurkat:
50ngml
 1, ML-1: 10ngml
 1, K562: 250ngml
 1) in the presence or absence of ATO (500ngml
 1). (A) Apoptotic cell death was measured 12h post
treatment by annexin V staining. One representative dot plot image from three independent experiments is shown. (B) Western blot analysis of pro-
caspase-3 and PARP cleavage in Jurkat cells treated with TRAIL and ATO for 10h. The figure shows one representative picture of three independent
experiments. (C) DEVDase activity in TRAIL- and ATO-treated Jurkat cells. DEVDase activity was measured in whole-cell lysates with a kinetic assay.
Enzyme activity was expressed in nmole AMC released per minute by 1mg total cellular protein. The chart represents the result of three independent
experiments 7s.d.
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snuclear condensation (data not shown), pro-caspase-3 processing
and activation, as well as cleavage of the caspase-3 substrate
protein PARP (Figure 2B and C).
Sensitisation by ATO is caspase-8 dependent
To delineate the mechanism by which low-dose ATO modifies
sensitivity to TRAIL, activation of pro-caspase-8 in Jurkat and
K562 cells was examined by following pro-caspase-8 cleavage with
Western blotting (Figure 3A and B) and by a fluorescent IETDase
assay (Figure 3C and D). In Jurkat cells, treatment with TRAIL
alone induced some pro-caspase-8 processing, which was detect-
able after 2h treatment (Figure 3A). Longer incubation with TRAIL
led only to a marginal increase in pro-caspase-8 processing.
Combined treatment with TRAIL and ATO induced pro-caspase-8
processing similar to TRAIL alone at 2h; however, as the
incubation time increased, a much more pronounced, almost
complete processing of pro-caspase-8 was detectable (Figure 3A).
In addition to the p43/p41 cleavage product, the fully processed
p18 caspase-8 subunit was also detectable in the combined
treatments (data not shown), indicating the lack of c-FLIPL-
mediated inhibition of caspase-8 (Krueger et al, 2001). Measure-
ment of IETDase activity reflected the same pattern with high
enzyme activity detectable only in the combination treatment
peaking at 6h of treatment (Figure 3C). In K562 cells, TRAIL or
ATO alone failed to induce detectable pro-caspase-8 processing or
activity over the 10h incubation time (Figure 3B and D).
Combined treatment with TRAIL and ATO for 10h, however,
induced pro-caspase-8 cleavage and a pronounced IETDase
activity.
In order to examine the requirement of caspase-8 in the process,
we used two approaches. Prior to treatment with TRAIL and ATO,
ML-1, K562 and Jurkat cells were treated with the caspase inhibitor
IETD.fmk, which is thought to preferentially target caspase-8 and
-10. Pretreatment with IETD.fmk partially prevented the synergis-
tic action of TRAIL and ATO in all the three cell lines tested
(Figure 4A). In the second approach, we used a caspase-8-deficient
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sJurkat cell line. In these cells, 24h treatment with ATO had minor
cytotoxic effect, similar to that found in wild-type Jurkat cells.
Addition of TRAIL in combination with ATO however, caused no
increase in cell death, providing compelling evidence for a caspase-
8-dependent action of the combined TRAIL and ATO treatment
(Figure 4B). Requirement for caspase-8 further proves that ATO, at
the concentrations used, primarily acts to reactivate the TRAIL
death pathway, not as a TRAIL-independent cytotoxic stimulus.
ATO increases DR5 cell surface expression
As TRAIL and ATO enhanced caspase-8 activation and their
synergistic action was caspase-8 dependent, it prompted us to
identify whether components of the DISC complex are affected by
ATO. The cell surface expression of DR4, DR5 and the two decoy
receptors, DcR1 and DcR2, was assessed in Jurkat cells. Although
there was no change in the expression of the two decoy receptors
and DR4, the cell surface expression of DR5 was increased after 6h
treatment with ATO (Figure 5A).
ATO affects phosphorylation state of Akt
Akt is a serine/threonine kinase, a target of the phosphatidylino-
sitol 3 kinase (Brazil et al, 2002). It has a strong antiapoptotic and
proliferative function and is known to be activated (phosphory-
lated) in several leukaemias. Jurkat cells also have considerable
basal Akt activity. Examination of the effect of ATO on Akt
phosphorylation in Jurkat cells by Western blotting revealed that
ATO treatment resulted in a rapid (4–6h) and significant decrease
in Akt phosphorylation. The decrease in the level of phosphory-
lated Akt (P-Akt) was due to dephosphorylation of Akt, rather then
a reduction in total Akt protein levels (Figure 5B).
In order to address the possible link between Akt and TRAIL
sensitivity, ATO was replaced with the PI3K inhibitor LY294002
(20mM) in the combination treatment with TRAIL. Pretreatment
of cells with LY294002 for 1h also led to increased TRAIL
responsiveness. Cell death measured by annexin V staining
(Figure 6A) synergistically increased after combined treatment
and cells showed features of apoptosis, including typical morpho-
logical changes (data not shown), pro-caspase-3 processing and
activation (Figure 6B and C). Akt phosphorylation was also
examined after treatment with the PI3K inhibitor LY294002 in
order to compare the Akt inhibiting potential of ATO and
LY294002. Treatment with LY294002 caused rapid and complete
dephosphorylation of Akt in 4h (Figure 6E). Arsenic trioxide also
induced similar, although not complete, inhibition of Akt after 4h
(Figure 6E).
Since treatment with ATO increased cell surface expression of
DR5, we examined if treatment with LY294002 mimicked this
effect. A treatment of Jurkat cells with LY294002 for 4h, although
to a lesser extent, also increased cell surface expression of DR5,
without affecting DR4 (Figure 6D). A possible alteration in c-FLIP,
a downstream target of Akt and a common inhibitor of TRAIL-
induced apoptosis was also examined (Figure 6E). We found that
treatment with either ATO or LY294002 caused a rapid and
pronounced drop in the expression of the short form of c-FLIP,
detectable after 4h treatment, pointing to a possible common
mechanism of action. Together, these data suggest that the
mechanism by which ATO enhances TRAIL sensitivity involves
inhibition of Akt and primarily targets components of the DR5
DISC complex.
DISCUSSION
Elemental arsenic has been used for centuries in medication and
arsenic was the first successful treatment for CML. Recently, the
trioxide derivative of arsenic has been shown to have marked
activity against relapsed APL inducing complete remission in 87%
of patients with only minimal side effects (Soignet et al, 2001;
Douer and Tallman, 2005). The multiple mechanisms of action of
ATO suggest that it may have antitumour activity in malignancies
other than APL and that it may be used in combination with other
agents. In the present study, we examined the mechanism of ATO-
mediated sensitisation of cancer cells to TRAIL-induced apoptosis.
We found that ATO specifically enhanced TRAIL-mediated cell
death in leukaemic cells, but not in other cancer cell types. Our
results indicate that the mechanism involves inhibition of the
PI3K/Akt pathway, and modulation of the TRAIL receptor DISC
components FLIPS and DR5.
Studying the mechanism of ATO-mediated sensitisation re-
vealed that combined treatment of Jurkat and K562 cells with
TRAIL and ATO led to increased processing and activation of
pro-caspase-8. The synergistic apoptosis-inducing effect appeared
to be caspase-8 dependent, as IETD.fmk-treated and caspase-8-
deficient cells were resistant to combined TRAIL and ATO-induced
apoptosis. As in most haematopoietic cells, TRAIL induces the
type I pathway, that is, mitochondrial amplification is not
required, and our findings suggested that the synergistic effect is
at the level of the DISC. To understand this effect further, we
examined the components of the DISC and observed early
upregulation of DR5 along with downregulation of c-FLIPS.
Upregulation of DR5 has been reported following treatment of
different cancer cell lines with a variety of anticancer agents, where
both p53-dependent and -independent mechanisms are recognised
(Wang and El-Deiry, 2003; Insinga et al, 2005). Following
treatment with ATO, myeloma cell lines with varying p53 status,
all showed upregulation of DR4 and DR5 and synergy with TRAIL
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Figure 5 Aarsenic trioxide affects Akt phosphorylation and DR5 cell
surface expression. (A) Flow cytometric analysis of cell surface expression
of TRAIL receptors DR4, DR5, DcR1 and DcR2 in Jurkat cells after
treatment with 500ngml
 1 ATO for 6h. (B) Western blot analysis of
phosphorylated Akt and total cellular Akt in Jurkat cells treated with
50ngml
 1 TRAIL in the presence or absence of 500ngml
 1 ATO for the
indicated times. b-Actin was used as a loading control. In all cases, one
representative image of three independent experiments is shown.
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mutated, our data confirm that p53 is not required for ATO-
mediated surface induction of DR5 (Cheng and Haas, 1990; Trepel
et al, 1997).
The observed decline in c-FLIPS levels following ATO is
particularly interesting. c-FLIP exists in various isoforms, the
best-characterised are c-FLIP long (c-FLIPL) and c-FLIP short
(c-FLIPS). c-FLIP has homology to caspases-8, and is able to
inhibit apoptosis by acting as a competitive antagonist of caspase-8
(Irmler et al, 1997). Overexpression and knock down studies as
well as reported correlations between c-FLIP levels and reduced
sensitivity to apoptosis implicate c-FLIP as a key inhibitor of death
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In Jurkat cells, ATO treatment caused a pronounced decrease in
c-FLIPS expression, detectable very early, after 4h treatment.
Decreased c-FLIP levels together with increased DR5 cell surface
expression could lead to an increased pro-caspase-8 to c-FLIP ratio
in the DISC resulting in enhanced pro-caspase-8 activation and
eventually cell death. In line with this hypothesis, we detected a
strong increase in pro-caspase-8 cleavage and activity after 4 and
6h treatment with TRAIL and ATO.
We also demonstrated that ATO treatment resulted in inhibition
of the serine/threonine kinase Akt (Brazil et al, 2002). Further-
more, blocking the PI3K-mediated activation of Akt led to similar
effects to that seen with ATO including DR5 upregulation, c-FLIPS
downregulation and greatly increased responsiveness to TRAIL.
From these observations we conclude that inhibition of Akt is
sufficient to restore TRAIL sensitivity, and the TRAIL-sensitising
effect of ATO is at least in part due to inhibition of Akt. Akt is
frequently activated in various cancers and moreover, high levels
of phosphorylated (activated) Akt is a poor prognostic indicator in
CML (Vivanco and Sawyers, 2002; Xu et al, 2003; Thompson and
Thompson, 2004; Grandage et al, 2005). To promote cell survival,
Akt phoshorylates and inhibits the pro-apoptotic protein BAD,
downregulates the expression of Bim and at the same time
upregulates antiapoptotic proteins, such as c-FLIP, IAPs (inhibitor
of apoptosis proteins) and Bcl-2 by activating NF-kB (Thompson
and Thompson, 2004). Akt is also known to mediate TRAIL
resistance (Nam et al, 2003). A constitutively activated Akt
protected HL-60 cells (an APL cell line) from TRAIL-induced
apoptosis through a mechanism involving NF-kB activation and c-
FLIPL upregulation, all of which could be reversed by treatment
with PI3K inhibitors (Bortul et al, 2003). These findings are similar
to our own observations, although the authors of this report did
not find any change in cell surface expression of death receptors,
highlighting that the response to Akt inhibition is likely to be cell
type specific.
As yet, we cannot rule out that other mechanisms also
contribute to the TRAIL-potentiating effect of ATO. For example,
ATO is a potent inducer of histone hyperacetylation (Perkins et al,
2000; Chen et al, 2001). While the present manuscript was in
preparation, GM Cohen’s lab published that histone deacetylase
inhibitors, in very low concentrations, are able to sensitise TRAIL-
resistant chronic lymphocytic leukaemia cells (Inoue et al, 2004).
The mechanism they revealed involves DR5 upregulation, facili-
tated TRAIL receptor DISC formation and enhanced caspase-8
processing, many features similar to our findings.
In summary, our data provide for the first time a potential
new usage of ATO, that is, in combination with TRAIL as an
antieukemic agent. At low, easily achievable concentrations,
ATO can reverse TRAIL resistance, probably in part due to
inhibition of Akt. While Akt inhibitors are not yet clinically
available, our results suggest that ATO, an already approved
medication, can achieve the same effect and offers a combina-
tion therapy with TRAIL as a novel systemic therapy for
leukaemias.
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